Judgment_paragraph 153 · AstraZeneca AB and AstraZeneca plc v European Commission (T-321/05)

153Therefore, although, as is apparent from the Commission’s previous decisions referred to in paragraph 108 above, the applicants are justified in observing that it is necessary to take account of differences between medicines’ modes of action where they give rise to different therapeutic uses and to disregard them where the medicines in question have a similar therapeutic use, they cannot claim that the Commission did not take therapeutic use into consideration in the present case. It is apparent from the contested decision that the Commission took due account of those therapeutic uses in its analysis.

AstraZeneca AB and AstraZeneca plc v European Commission (T-321/05)

Key facts

History · 1 version

Connections